(R)-(-)-N-benzyl-3-methylpiperidine | 37675-26-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (R)-(-)-N-benzyl-3-methylpiperidine
• 英文别名: 1-benzyl-3-methylpiperidine；(3R)-1-benzyl-3-methylpiperidine
• CAS: 37675-26-6
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: VUEWBPBFUKIDKK-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-benzyl-3-methylpyridin-1-ium bromide 在 bis(1,5-cyclooctadiene)rhodium(I) trifluoromethanesulfonate 、 (R)-(-)-[(S)-2-(diphenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 2,2,2-三氟乙醇 为溶剂， 50.0 ℃ 、5.0 MPa 条件下， 反应 16.0h， 以57%的产率得到
  参考文献：
  名称：

  3取代吡啶鎓盐的不对称氢化

  摘要：

  在N-苄基化3-取代的吡啶鎓盐不对称加氢成相应的哌啶中，使用等量的有机碱会导致高对映体过量。实际上，在存在Et 3 N的情况下，Rh‐JosiPhos催化剂可还原一系列ee值高达90％的吡啶鎓盐。通过涉及各种反应中间体的分离和同位素标记实验的机理研究阐明了该碱的作用。另外，该研究为涉及二氢吡啶中间体的对映体确定步骤提供了一些证据。

  DOI：

  10.1002/chem.201601501

文献信息

• [EN] NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 6-AMINO-QUINOLINONE ET DÉRIVÉS EN TANT QU'INHIBITEURS DE BCL6
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018108704A1

  公开（公告）日：2018-06-21

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式(I)的化合物，其中基团R1至R5、X、Y和W具有权利要求和说明中给定的含义，它们作为BCL6的抑制剂的用途，含有这种化合物的药物组合物以及它们作为药物的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。
• [EN] TRICYCLIC PYRAZOL AMINE DERIVATIVES<br/>[FR] DÉRIVÉS TRICYCLIQUES DE PYRAZOLAMINE
  申请人：MERCK SERONO SA

  公开号：WO2011058149A1

  公开（公告）日：2011-05-19

  This invention relates to compounds of Formula (I*) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.

  这项发明涉及到 Formula (I*) 的化合物作为 Pi3k 抑制剂，用于治疗自身免疫疾病、炎症性疾病、多发性硬化等疾病，以及癌症等其他疾病。
• A hydrogen borrowing annulation strategy for the stereocontrolled synthesis of saturated aza-heterocycles
  作者：Anna E. R. Chamberlain、Kieran J. Paterson、Roly J. Armstrong、Heather C. Twin、Timothy J. Donohoe

  DOI：10.1039/d0cc00903b

  日期：——

  A hydrogen borrowing annulation strategy enables the stereocontrolled synthesis of C2, C3 and C4-substituted saturated aza-heterocycles.

  一种氢借位缩合策略实现了C2、C3和C4取代饱和氮杂环的立体控制合成。
• NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS
  申请人：Bertrand Isabelle

  公开号：US20090111808A1

  公开（公告）日：2009-04-30

  The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.

  本专利申请涉及式(I)的化合物，其中R1和R2与它们所连接的氮原子结合形成单环或双环饱和含氮环; 它们的制备及其用作H3受体配体，用于治疗例如阿尔茨海默病等中枢神经系统疾病。
• Novel Bicyclic Antibiotics
  申请人：Gaucher Berangere

  公开号：US20120040957A1

  公开（公告）日：2012-02-16

  Compounds of formula (I) wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; R1 and R2, independently of one another, represent hydrogen or a substituent selected from hydroxy, halogen, carboxy, amino, C1-C6alkylamino, di(C1-C6alkyl)amino, mercapto, cyano, nitro, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylthio, C1-C6alkylamino-carbonyloxy, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkylcarbonyloxy, C1-C6alkyl-sulfonyloxy, C1-C6heteroalkylcarbonyloxy, C5-C6heterocyclyl-carbonyloxy, C1-C6heteroalkyl, C1-C6heteroalkoxy, wherein heteroalkyl, heteroalkoxy groups or heterocyclyl comprise 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, in which substituents the alkyl moieties are unsubstituted or further substituted by halogeno, cyano, hydroxy, C1-C4alkoxy, C1-C4alkylcarbonyl, C1-C4alkoxycarbonyl, unsubstituted or substituted phenoxy or phenylcarbonyl, unsubstituted or substituted C5-C6heterocyclyl or carboxy; A1 represents a divalent group of one of the formulae —O—(CH 2 ) m —(CH 2 )—, —S—(CH 2 ) m —(CH 2 )— or —(C═O)O—(CH 2 ) m —(CH 2 )—, wherein the (CH 2 ) m moiety is optionally substituted by C1-C4alkyl, C2-C4alkenyl, C3-C6cycloalkyl, C3-C6cycloalkylmethyl, morpholinomethyl, halogen, carboxy, hydroxy, C1-C4alkoxy; C1-C4alkoxyC1-C4alkyl, C1-C4alkoxy(C1-C4alkylenoxy)C1-C4alkyl, benzyloxyC1-C4alkyl, amino, mono- or di-(C1-C4alkyl)amino or acylamino, in which substituents the alkyl moieties can be further substituted by 1 or more fluoro atoms m is 0, 1 or 2, provided that the nunber of atoms in the direct chain between the two terminal valencies of A 1 is at least 3, which group A 1 is linked to A 2 via the terminal (CH 2 )-moiety; A 2 is a group selected from C 3 -C 8 cycloalkylene; saturated and unsaturated 4 to 8 -membered heterocyclodiyl with 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, which group A 2 is unsubstituted or substituted; R 4 represents hydrogen or C 1 -C 4 alkyl; A 3 represents C 1 -C 4 alkylene, C 2 -C 4 alkenylene, >C═O, —C(O)C 1 -C 3 alkylene-, —C(═O)NH—, or a group selected from —C 2 H 4 NH—, —C 2H 4 O—, and —C 2 H 4 S— being linked to the adjacent NR 4 -group via the carbon atom; and G represents aryl or heteroaryl, which is unsubstituted or substituted and n is 0, 1 or 2; or a pharmaceutically acceptable salts, hydrates or solvates thereof are valuable antibacterial agents.

  化合物式(I)中，其中X1、X3、X4和X6分别独立地表示氮原子或CR2，但至少其中一个表示氮原子；X2表示C-H、C-(C1-C6烷基)、C-(C1-C6烷氧基)、C-卤素、C-COOH；X5表示C-H或C-(C1-C6烷基)、C-卤素；R1和R2独立地表示氢或从羟基、卤素、羧基、氨基、C1-C6烷基氨基、二(C1-C6烷基)氨基、巯基、氰基、硝基、C1-C6烷基、C1-C6烷氧基、C1-C6烷基硫基、C1-C6烷基氨基羰氧基、C2-C6烯基、C2-C6炔基、C1-C6烷基羰氧基、C1-C6烷基磺酰氧基、C1-C6杂烷基羰氧基、C5-C6杂环基羰氧基、C1-C6杂烷基、C1-C6杂烷氧基中选择的取代基，其中杂烷基、杂烷氧基或杂环基包括1、2或3个从氮、氧和硫选择的杂原子，在这些取代基中，烷基基团未取代或进一步取代为卤代、氰基、羟基、C1-C4烷氧基、C1-C4烷基羧基、C1-C4烷氧羰基、未取代或取代的苯氧基或苯基羧基、未取代或取代的C5-C6杂环基或羧基；A1表示一个二价基团，其中之一为式之一的基团-O-(CH2)m-( )-、-S-( )m-( )-或-(C═O)O-( )m-( )-，其中( )m基团可以选择地被C1-C4烷基、C2-C4烯基、C3-C6环烷基、C3-C6环烷基甲基、吗啉基甲基、卤素、羧基、羟基、C1-C4烷氧基取代；C1-C4烷氧基C1-C4烷基、C1-C4烷氧基(C1-C4烷氧基)C1-C4烷基、苄氧基C1-C4烷基、氨基、单取代或双取代(C1-C4烷基)氨基或酰基氨基，在这些取代基中，烷基基团可以进一步取代1个或多个氟原子，m为0、1或2，前提是A1的两个端面价之间的直链原子数至少为3，该基团A1通过端面( )基团与A2相连；A2是选择自C3-C8环烷基、饱和和不饱和的1、2或3个从氮、氧和硫选择的杂环二基，该基团A2未取代或取代；R4表示氢或C1-C4烷基；A3表示C1-C4烷基、C2-C4烯基、>C═O、-C(O)C1-C3烷基、-C(═O)NH-或选择自-C2H4NH-、-C2H4O-和-C2H4S-的基团，通过碳原子与相邻的NR4基团相连；G表示未取代或取代的芳基或杂芳基，其中n为0、1或2；或其药学上可接受的盐、水合物或溶剂。这些化合物是有价值的抗菌剂。